Compass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Compass Therapeutics (NASDAQ:CMPX) posted its quarterly earnings results on Thursday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), FiscalAI reports.

Compass Therapeutics Stock Up 8.0%

CMPX traded up $0.16 during trading hours on Friday, hitting $2.15. The stock had a trading volume of 3,825,555 shares, compared to its average volume of 2,660,902. Compass Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.88. The company’s fifty day simple moving average is $2.09 and its 200 day simple moving average is $3.86. The stock has a market cap of $387.19 million, a PE ratio of -5.37 and a beta of 0.92.

Hedge Funds Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the business. Strs Ohio bought a new position in Compass Therapeutics in the 1st quarter worth approximately $34,000. Creative Planning purchased a new stake in shares of Compass Therapeutics during the second quarter worth $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the 2nd quarter valued at $84,000. Invesco Ltd. lifted its holdings in Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after purchasing an additional 21,578 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CMPX. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a report on Monday, June 1st. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price on the stock. Finally, Piper Sandler boosted their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $11.77.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.